Benefits of AstraZeneca vaccine outweigh risks
22 Apr 2021 | 4 mins (including 1 min video)
Risk versus benefit modelling by researchers at The University of Western Australia has weighed up the potential of harm from an extremely rare AstraZeneca vaccine blood clot complication against COVID-19 ICU admission from not being vaccinated.
Associate Professor Matthew Linden from UWA’s School of Biomedical Sciences said the modelling had identified the implications for each adult age group of waiting out the months it might take Australia to secure further supplies of an alternative vaccine.
Based on Australia’s recent low risk of COVID exposure and a possible delay of 16 weeks for an alternative vaccine, the results suggested only under 50-year-olds should consider “holding out” for an alternative vaccine. For them, there was no clear benefit from AstraZeneca vaccination when virus transmission was low.
Benefits of AstraZeneca vaccine outweigh risks of blood clots for over-50s miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.